ArticleResearch square2026
Novel Plasma Proteins Associated With Alzheimer's Disease Risk in APOE ε4 Carriers and Non-carriers.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Background: Whether plasma protein associations with Alzheimer's disease (AD) differ by genetic risk remains unclear. Methods: We studied 18,212 UK Biobank participants aged ≥ 60 years with Olink Explore 3072 proteomic data, APOE genotypes, and AD polygenic risk scores. Protein-by-genetic risk interactions were screened, followed by genetic risk-stratified association and mediation analyses in Cox models. Results: During 12.8 years of follow-up, 374 participants developed AD. APOE ε4 carriers had higher AD risk than non-carriers (HR = 7.79 [6.18-9.81]), with the greatest risk among ε4 homozygotes (HR = 17.73 [13.36-23.51]). Stratified analyses identified AD-associated proteins among APOE ε4 non-carriers (n = 85), ε4 carriers (n = 10), and low-, intermediate-, and high-AD-PRS groups (n = 10, 1, and 2, respectively), including 94 newly identified proteins. APOE protein, MENT, and GFAP mediated 34.49%, 25.01%, and 11.47% of the APOE ε4-AD association. Conclusions: Genetic risk stratification revealed heterogeneous protein-AD associations and genotype-dependent proteomic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.